Former Lawyer Went From $50K To $5.3M Trading Options
Slaving away for 70 hrs a week as a lawyer in Chicago, I was miserable.

I ran into guys who worked the trading floor at the local exchange. I began trading the same way they did. I started out with $50K (much more than I needed, actually).

I grew my $50K into $5.3M
I'll show you how I did it here.
Michael D. Goldberg, insider at CareDx

Michael D. Goldberg Insider Information

Director of CareDx
Michael Goldberg has served as a member and chairman of our board of directors since November 2011. From January 2005 to May 2011, Mr. Goldberg was a partner at Mohr Davidow Ventures, a venture capital firm, where he led life sciences investments in the area of molecular diagnostics, personalized medicine, and wireless healthcare. From October 2000 to December 2004, Mr. Goldberg operated a management and financial consultancy business. In 1995, Mr. Goldberg founded OnCare, Inc., an oncology disease management company, and served as chairman until August 2001 and as chief executive officer until March 1999. In 1987, Mr. Goldberg founded Axion, Inc., a cancer treatment services company, and served as chief executive officer until its sale to Bristol-Myers Squibb in 1995. Prior to Axion, Mr. Goldberg was a partner at the venture capital firm, Sevin Rosen Management Company, from 1985 to 1987, where he established the firm’s life science practice, and was director of corporate development at Cetus Corporation from 1981 to 1985. Mr. Goldberg has served as a member of the board of directors of numerous companies in the biotech and health sciences industry, and currently serves as executive chairman of DNAnexus, Inc. Mr. Goldberg has served on boards and advisory boards of a number of industry, academic, and public policy institutions in biotechnology and finance, including the board of the Independent Citizens Oversight Committee, which is the governing board for the California Institute for Regenerative Medicine, the board of the Western Association of Venture Capitalists, the advisory boards of the Harvard Center for Genetics and Genomics, the Berkeley Center for Law and Technology, and the UCSF Center for Translational and Policy Research on Personalized Medicine. Mr. Goldberg holds a BA from Brandeis University and an MBA from the Stanford Graduate School of Business.

What is Michael D. Goldberg's net worth?

The estimated net worth of Michael D. Goldberg is at least $1.40 million as of April 11th, 2022. Mr. Goldberg owns 62,267 shares of CareDx stock worth more than $1,395,403 as of July 4th. This net worth estimate does not reflect any other investments that Mr. Goldberg may own. Learn More about Michael D. Goldberg's net worth.

How do I contact Michael D. Goldberg?

The corporate mailing address for Mr. Goldberg and other CareDx executives is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. CareDx can also be reached via phone at (415) 287-2300 and via email at [email protected] Learn More on Michael D. Goldberg's contact information.

Has Michael D. Goldberg been buying or selling shares of CareDx?

Michael D. Goldberg has not been actively trading shares of CareDx within the last three months. As far as recent transactions, 0 shares of the firm's stock in a transaction that occurred on Monday, July 4th. Learn More on Michael D. Goldberg's trading history.

Who are CareDx's active insiders?

CareDx's insider roster includes Paul Adler (CEO), George Bickerstaff, III (Director), Ankur Dhingra (CFO), Michael Goldberg (Director), William Hagstrom (Director), Sasha King (CMO), Peter Maag (Insider), Reginald Seeto (Insider), Ralph Snyderman (Director), and Thomas Thomas (Director). Learn More on CareDx's active insiders.

Are insiders buying or selling shares of CareDx?

In the last twelve months, CareDx insiders bought shares 1 times. They purchased a total of 5,000 shares worth more than $211,700.00. In the last twelve months, insiders at the sold shares 27 times. They sold a total of 156,443 shares worth more than $8,087,835.54. The most recent insider tranaction occured on May, 11th when Director Grace Colon sold 5,179 shares worth more than $119,168.79. Insiders at CareDx own 4.6 % of the company. Learn More about insider trades at CareDx.

Information on this page was last updated on 5/11/2022.

Michael D. Goldberg Insider Trading History at CareDx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/11/2022Sell500$36.01$18,005.0062,267View SEC Filing Icon  
3/9/2022Sell500$33.41$16,705.00View SEC Filing Icon  
2/9/2022Sell500$42.96$21,480.00View SEC Filing Icon  
1/10/2022Sell500$42.97$21,485.00View SEC Filing Icon  
12/9/2021Sell500$45.41$22,705.00View SEC Filing Icon  
11/9/2021Sell500$47.54$23,770.00View SEC Filing Icon  
10/11/2021Sell500$62.50$31,250.00View SEC Filing Icon  
5/10/2021Sell15,442$68.94$1,064,571.4873,945View SEC Filing Icon  
12/14/2020Sell30,000$70.19$2,105,700.0071,784View SEC Filing Icon  
5/11/2020Sell10,000$29.86$298,600.0080,765View SEC Filing Icon  
3/14/2019Sell50,000$37.36$1,868,000.0084,740View SEC Filing Icon  
7/22/2014Buy25,000$10.00$250,000.00View SEC Filing Icon  
See Full Table

Michael D. Goldberg Buying and Selling Activity at CareDx

This chart shows Michael Goldberg's buying and selling at CareDx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CareDx Company Overview

CareDx logo
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $22.41
Low: $21.40
High: $22.52

50 Day Range

MA: $25.05
Low: $20.49
High: $34.07

2 Week Range

Now: $22.41
Low: $19.34
High: $92.55


618,400 shs

Average Volume

817,234 shs

Market Capitalization

$1.19 billion

P/E Ratio


Dividend Yield



Tailor an Options Trading Strategy to Fit Your Needs
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.

Take your trading to the next level with the Options Strategy Guide.
Download your FREE Options Strategy Guide Today.